Semaglutide reduces blood pressure through direct action on GLP-1 receptors in vascular smooth muscle cells (VSMCs), not through weight loss or endothelial effects as previously assumed. Mice lacking VSMC GLP-1 receptors showed no blood pressure reduction with semaglutide treatment, while the drug's effects on glucose control and weight remained intact. The mechanism involves enhanced kidney filtration, increased sodium excretion, and direct arterial relaxation.
This finding fundamentally reframes how we understand semaglutide's cardiovascular benefits. Rather than being secondary to metabolic improvements, blood pressure reduction appears to be a direct vascular effect—potentially explaining why cardiovascular benefits in clinical trials often exceed what weight loss alone would predict. For the millions taking GLP-1 agonists, this suggests dual therapeutic value: metabolic control plus independent vascular protection. However, this mouse study requires human validation, as vascular physiology differs significantly between species. The discovery opens new therapeutic avenues for targeting VSMCs in hypertension treatment, though translating these mechanistic insights into clinical practice will require careful study of dosing, timing, and patient selection.